Selected article for: "comprehensive testing and tracing testing"
Author: Jendrny, Paula; Twele, Friederike; Meller, Sebastian; Schulz, Claudia; von Köckritz-Blickwede, Maren; Osterhaus, Albertus Dominicus Marcellinus Eras; Ebbers, Hans; Ebbers, Janek; Pilchová, Veronika; Pink, Isabell; Welte, Tobias; Manns, Michael Peter; Fathi, Anahita; Addo, Marylyn Martina; Ernst, Christiane; Schäfer, Wencke; Engels, Michael; Petrov, Anja; Marquart, Katharina; Schotte, Ulrich; Schalke, Esther; Volk, Holger Andreas
Title: Scent dog identification of SARS-CoV-2 infections in different body fluids
  • Cord-id: yrdzg7wz
  • Document date: 2021_7_27
    • ID: yrdzg7wz
    Snippet: BACKGROUND: The main strategy to contain the current SARS-CoV-2 pandemic remains to implement a comprehensive testing, tracing and quarantining strategy until vaccination of the population is adequate. Scent dogs could support current testing strategies. METHODS: Ten dogs were trained for 8 days to detect SARS-CoV-2 infections in beta-propiolactone inactivated saliva samples. The subsequent cognitive transfer performance for the recognition of non-inactivated samples were tested on three differe
    Document: BACKGROUND: The main strategy to contain the current SARS-CoV-2 pandemic remains to implement a comprehensive testing, tracing and quarantining strategy until vaccination of the population is adequate. Scent dogs could support current testing strategies. METHODS: Ten dogs were trained for 8 days to detect SARS-CoV-2 infections in beta-propiolactone inactivated saliva samples. The subsequent cognitive transfer performance for the recognition of non-inactivated samples were tested on three different body fluids (saliva, urine, and sweat) in a randomised, double-blind controlled study. RESULTS: Dogs were tested on a total of 5242 randomised sample presentations. Dogs detected non-inactivated saliva samples with a diagnostic sensitivity of 84% (95% CI: 62.5–94.44%) and specificity of 95% (95% CI: 93.4–96%). In a subsequent experiment to compare the scent recognition between the three non-inactivated body fluids, diagnostic sensitivity and specificity were 95% (95% CI: 66.67–100%) and 98% (95% CI: 94.87–100%) for urine, 91% (95% CI: 71.43–100%) and 94% (95% CI: 90.91–97.78%) for sweat, 82% (95% CI: 64.29–95.24%), and 96% (95% CI: 94.95–98.9%) for saliva respectively. CONCLUSIONS: The scent cognitive transfer performance between inactivated and non-inactivated samples as well as between different sample materials indicates that global, specific SARS-CoV-2-associated volatile compounds are released across different body secretions, independently from the patient’s symptoms. All tested body fluids appear to be similarly suited for reliable detection of SARS-CoV-2 infected individuals. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-021-06411-1.

    Search related documents:
    Co phrase search for related documents
    • accurate affordable rapid and low prevalence: 1
    • ache headache and acute respiratory distress syndrome: 1
    • ache headache and low infection: 1
    • acute respiratory distress syndrome and low infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
    • acute respiratory distress syndrome and low infection risk: 1, 2
    • acute respiratory distress syndrome and low number: 1, 2, 3, 4, 5
    • acute respiratory distress syndrome and low prevalence: 1, 2, 3, 4, 5, 6
    • acute respiratory distress syndrome and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
    • acute respiratory distress syndrome severe pneumonia and low number: 1
    • acute respiratory distress syndrome severe pneumonia and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • additional table and low number: 1
    • low infection and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • low number and lung disease: 1, 2, 3, 4
    • low prevalence and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9